Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Pipeline Review, H2 2016

Publisher Name :
Date: 14-Sep-2016
No. of pages: 58

Note*:

*Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Global Markets Direct's, ‘Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Pipeline Review, H2 2016', provides in depth analysis on Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) targeted pipeline therapeutics.

The report provides comprehensive information on the Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP)

  • The report reviews Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

  • The report reviews key players involved in Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) targeted therapeutics and enlists all their major and minor projects

  • The report assesses Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

  • The report summarizes all the dormant and discontinued pipeline projects

  • The report reviews latest news and deals related to Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

  • Identify and understand the targeted therapy areas and indications for Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP)

  • Identify the use of drugs for target identification and drug repurposing

  • Identify potential new clients or partners in the target demographic

  • Develop strategic initiatives by understanding the focus areas of leading companies

  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

  • Devise corrective measures for pipeline projects by understanding Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) development landscape

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Pipeline Review, H2 2016

Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) Overview 7
Therapeutics Development 8
Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Products under Development by Stage of Development 8
Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Products under Development by Therapy Area 9
Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Products under Development by Indication 10
Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Pipeline Products Glance 11
Late Stage Products 11
Early Stage Products 12
Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Products under Development by Companies 13
Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Products under Development by Universities/Institutes 15
Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Therapeutics Assessment 17
Assessment by Monotherapy/Combination Products 17
Assessment by Mechanism of Action 18
Assessment by Route of Administration 19
Assessment by Molecule Type 20
Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Companies Involved in Therapeutics Development 21
Amgen Inc. 21
Bristol-Myers Squibb Company 22
Chong Kun Dang Pharmaceutical Corp. 23
Japan Tobacco Inc. 24
Kowa Company, Ltd. 25
Merck & Co., Inc. 26
Pfizer Inc. 27
Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Drug Profiles 28
AMG-899 - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
anacetrapib - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
BMS-795311 - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
CKD-519 - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
dalcetrapib - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
HL-16 - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
K-312 - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
PF-04445597 - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Dormant Projects 41
Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Discontinued Products 42
Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Featured News & Press Releases 45
Aug 23, 2016: DalCor Announces Opening of International Trial Sites for Its Dal-GenE Phase 3 Cardiovascular Outcomes Trial 45
Jul 18, 2016: DalCor Dalcetrapib Demonstrates Genotype-Dependent Effects on Cholesterol Efflux and Inflammation in Data Published by The Montreal Heart Institute in Circulation: Cardiovascular Genetics 45
Apr 26, 2016: DalCor Randomizes First Patient in the DalGenE Phase 3 Cardiovascular Outcomes Trial 46
Nov 13, 2015: Merck Provides Update on REVEAL Outcomes Study 48
Jun 08, 2015: DalCor Pharma licenses a late-stage investigational cardiovascular drug following major scientific discovery 48
Jun 03, 2015: Dezima Pharma's CETP Inhibitor, TA-8995, Phase 2b (TULIP) Study Results Published in The Lancet 49
Jan 12, 2015: A World First - Discovery of a personalized therapy for cardiovascular disease 50
Nov 13, 2014: Dezima Pharma Announces Complete Enrolment of CETP Inhibitor TA-8995 Study in Subjects With Isolated, Elevated Lipoprotein(a) Levels 50
Aug 29, 2014: Dezima Reports Positive Results in its Phase 2b TULIP Trial with CETP Inhibitor TA-8995 in Dyslipidemia 51
Jul 08, 2014: Dezima Pharma extends clinical development program for its CETP Inhibitor TA-8995 52
Jan 13, 2014: Dezima Pharma Completes Patient Enrolment for TULIP Phase 2B Study with CETP Inhibitor TA-8995 52
Aug 29, 2013: Dezima Pharma initiates Phase 2b TULIP study on CETP inhibitor program DEZ-001 53
Nov 05, 2012: Roche's Dalcetrapib Increases HDL Levels But Fails To Reduce Risk Of Cardiovascular Events, Study Finds 54
Aug 26, 2012: Merck Provides Update On Anacetrapib Development Program 55
May 07, 2012: Roche Provides Update On Phase III Study Of Dalcetrapib 55
Appendix 57
Methodology 57
Coverage 57
Secondary Research 57
Primary Research 57
Expert Panel Validation 57
Contact Us 57
Disclaimer 58

List of Tables

Number of Products under Development for, H2 2016 8
Number of Products under Development by Therapy Area, H2 2016 9
Number of Products under Development by Indication, H2 2016 10
Comparative Analysis by Late Stage Development, H2 2016 11
Comparative Analysis by Early Stage Products, H2 2016 12
Number of Products under Development by Companies, H2 2016 13
Products under Development by Companies, H2 2016 14
Number of Products under Investigation by Universities/Institutes, H2 2016 15
Products under Investigation by Universities/Institutes, H2 2016 16
Assessment by Monotherapy/Combination Products, H2 2016 17
Number of Products by Stage and Mechanism of Action, H2 2016 18
Number of Products by Stage and Route of Administration, H2 2016 19
Number of Products by Stage and Molecule Type, H2 2016 20
Pipeline by Amgen Inc., H2 2016 21
Pipeline by Bristol-Myers Squibb Company, H2 2016 22
Pipeline by Chong Kun Dang Pharmaceutical Corp., H2 2016 23
Pipeline by Japan Tobacco Inc., H2 2016 24
Pipeline by Kowa Company, Ltd., H2 2016 25
Pipeline by Merck & Co., Inc., H2 2016 26
Pipeline by Pfizer Inc., H2 2016 27
Dormant Projects, H2 2016 41
Discontinued Products, H2 2016 42
Discontinued Products (Contd..1), H2 2016 43
Discontinued Products (Contd..2), H2 2016 44

List of Figures

Number of Products under Development for, H2 2016 8
Number of Products under Development by Therapy Area, H2 2016 9
Number of Products under Development by Indication, H2 2016 10
Comparative Analysis by Late Stage Development, H2 2016 11
Comparative Analysis by Early Stage Products, H2 2016 12
Assessment by Monotherapy/Combination Products, H2 2016 17
Number of Products by Stage and Mechanism of Actions, H2 2016 18
Number of Products by Stage and Routes of Administration, H2 2016 19
Number of Products by Stage and Molecule Type, H2 2016 20
  • Global Biobanking Market Professional Survey Report 2017
    Published: 15-Nov-2017        Price: US 3500 Onwards        Pages: 119
    This report studies Biobanking in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from 2012 to 2016, and forecast to 2022. This report focuses on top manufacturers in global market, with production, price, revenue and market share for each manufacturer, covering - Beckman Coulter - Thermo Fisher - Panasonic - Sigma-Aldrich - SOL ......
  • United States Ion Indicators Market Report 2017
    Published: 15-Nov-2017        Price: US 3800 Onwards        Pages: 103
    In this report, the United States Ion Indicators market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report splits the United States market into seven regions: - The West - Southwest - The Middle Atlantic - New England - The South - The Midwest with sales (volume), revenue (value), market share and growth rate of I......
  • Global DNA Forensic Market Research Report 2017
    Published: 14-Nov-2017        Price: US 2900 Onwards        Pages: 119
    In this report, the global DNA Forensic market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of DNA Forensic in these regions, from 2012 to 2022 (forecast), covering - North America - Europe - China - Japan......
  • Global Somatostatin Sales Market Report 2017
    Published: 13-Nov-2017        Price: US 4000 Onwards        Pages: 114
    In this report, the global Somatostatin market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split global into several key Regions, with sales (K MT), revenue (Million USD), market share and growth rate of Somatostatin for these regions, from 2012 to 2022 (forecast), covering - United States - China - Europe - Japan - Sout......
  • United States Biosimulation Market Report 2017
    Published: 13-Nov-2017        Price: US 3800 Onwards        Pages: 102
    In this report, the United States Biosimulation market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report splits the United States market into seven regions: - The West - Southwest - The Middle Atlantic - New England - The South - The Midwest with sales (volume), revenue (value), market share and growth rate of Bi......
  • Global Somatostatin Market Professional Survey Report 2017
    Published: 13-Nov-2017        Price: US 3500 Onwards        Pages: 118
    This report studies Somatostatin in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from 2012 to 2016, and forecast to 2022. This report focuses on top manufacturers in global market, with production, price, revenue and market share for each manufacturer, covering - Merck - Sanofi - Lyomark Pharma - ALFA WASSERMANN - Polypeptide ......
  • Global Digital PCR (dPCR) Market Professional Survey Report 2017
    Published: 13-Nov-2017        Price: US 3500 Onwards        Pages: 116
    This report studies Digital PCR (dPCR) in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from 2012 to 2016, and forecast to 2022. This report focuses on top manufacturers in global market, with production, price, revenue and market share for each manufacturer, covering - Bio-Rad Laboratories - Life Technologies - Thermo Fisher Scientific......
  • Global Glycomics/Glycobiology Market Data Survey Report 2025
    Published: 11-Nov-2017        Price: US 1500 Onwards        Pages: 83
    Summary Glycomics is the comprehensive study of glycomes (the entire complement of sugars, whether free or present in more complex molecules of an organism), including genetic, physiologic, pathologic, and other aspects. Glycomics "is the systematic study of all glycan structures of a given cell type or organism" and is a subset of glycobiology. The term glycomics is derived from the chemical prefix for sweetness or a sugar, "glyco-", and was formed to follow the naming convention establi......
  • Global Glycomics/Glycobiology Market Research Report 2011-2023
    Published: 10-Nov-2017        Price: US 2450 Onwards        Pages: 79
    Summary Glycomics is the comprehensive study of glycomes (the entire complement of sugars, whether free or present in more complex molecules of an organism), including genetic, physiologic, pathologic, and other aspects. Glycomics "is the systematic study of all glycan structures of a given cell type or organism" and is a subset of glycobiology. The term glycomics is derived from the chemical prefix for sweetness or a sugar, "glyco-", and was formed to follow the naming convention......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs